Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Neil P. Shah(University of California, San Francisco), Kristina M. Gregory(National Comprehensive Cancer Network), Vivian G. Oehler(University of Washington), Ravi Bhatia(City Of Hope National Medical Center), Moshe Talpaz(University of Michigan–Ann Arbor), Tiffany Tanaka(UC San Diego Health System), B. Douglas Smith(Johns Hopkins University), Michael W. Drazer(Susan Thompson Buffett Foundation), Jessica K. Altman(Princess Margaret Cancer Centre), Leland Metheny(Cancer Institute (WIA)), Iskra Pusic(Washington University in St. Louis), Maria L. Amaya(University of Colorado Denver), Srinivas K. Tantravahi(University of Utah), Keith W. Pratz(Cancer Institute (WIA)), James E. Thompson(Roswell Park Comprehensive Cancer Center), Lori J. Maness(Susan Thompson Buffett Foundation), Jennifer E. Vaughn(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Michael Styler(Fox Chase Cancer Center), Peter Curtin(City Of Hope National Medical Center), Onyee Chan(Moffitt Cancer Center), Kebede H. Begna(Mayo Clinic), William Shomali(Stanford Medicine), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Hema Sundar, David T. Yang(University of Wisconsin Carbone Cancer Center), Robert H. Collins(Texas Oncology), Steven Tsai(University of Colorado Cancer Center), Joan Clements(Nierstichting), Joseph O. Moore(Cancer Institute (WIA)), Jeanna Welborn(UC Davis Comprehensive Cancer Center), Michal G. Rose(Yale Cancer Center), Sanjay Mohan(Breast Cancer Research Foundation), Ellin Berman(Memorial Sloan Kettering Cancer Center)
Cited by 116
Related Papers
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
|Journal of the National Comprehensive Cancer Network|2010|1.2k